Loading…
← CockpitCompetitor Analysis › 688796.SS Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class AOpen in the cockpit ↗

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class A688796.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.

≈ A China-based antibody-discovery/CRO platform, like a smaller Genentech-tools peerMomentum laggard 3
Mkt cap
$2.09B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$36.3M
20-day average traded
Fwd P/E
73.0×
forward earnings
ROIC−WACC
+1.8 pp
WACC 11.1%
Hurdle
-10 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥64.59
1D-2.1%
1W-16.7%
1M-27.8%
3M-56.4%
6M-32.9%
YTD+22.8%
1Yn/a
ATR %10.3%
52w lowhigh58.3% off high

What Biocytogen Pharmaceuticals (Beijing) does

Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.

Earns fees for supplying gene-edited mice and running research studies on them, plus up-front and milestone payments when drug makers license antibodies found with its RenMice platform. The same company is also listed in Hong Kong as 2315.

In one line: A China-based antibody-discovery/CRO platform, like a smaller Genentech-tools peer.

Products and services

  • Humanized mouse models
  • Antibody discovery services
  • In-house biologics pipeline

Customers

  • Pharma/biotech R&D partners

Where it sits in the supply chain

  • Biopharma tools
  • Antibody discovery
  • Humanized mouse models, biologics R&D

What could go right

  • Global biopharma outsourcing of antibody discovery

What could go wrong

  • Biotech funding-cycle sensitivity

Moat: narrow (IP / patents, installed base). Proprietary mouse-model platform used broadly by global biopharma partners.

Headquarters: Beijing, China · Employees: 1,443

Named competitors

Biocytogen Pharmaceuticals (Beijing) at a glance

Size Biocytogen Pharmaceuticals (Beijing) (688796.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $2.09B, the 1126th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥64.59 on 18 Nov 2026.

Performance Over six months the shares fell 32.9%, against +1.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 40.5% over the last twelve months (peer median +15.8%); the operating margin is 23.6% (peer median 12.4%).

Valuation It trades at 73.0× forward earnings against a peer median of 17.0× (3rd most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.8 points above its cost of capital (11.1% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 99688796.SS 68
Six months, rebased to 100: Biocytogen Pharmaceuticals (Beijing) against the median of its 20 peers (local-currency closes).

Biocytogen Pharmaceuticals (Beijing) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.65BCN¥1.34BCN¥999MCN¥720MCN¥548M
Revenue growth—+35%+39%+31%—
Gross profitCN¥1.29BCN¥940MCN¥684MCN¥423MCN¥308M
EBITDACN¥541MCN¥358MCN¥301M-CN¥128M-CN¥459M
Net incomeCN¥357MCN¥169MCN¥34.2M-CN¥385M-CN¥618M
Free cash flowCN¥134MCN¥260MCN¥159M-CN¥211M-CN¥563M
Capital expenditureCN¥272MCN¥85.6MCN¥37.8MCN¥127MCN¥247M
Total debtn/aCN¥919MCN¥1.27BCN¥1.32BCN¥1.27B

Quarterly statements and history in the cockpit →

Biocytogen Pharmaceuticals (Beijing) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%6886906257IGILFSLTIC77993264SAGILITY001267KWS601965SYNGENE002091NSP300140688596PSGVVX002310HOFI688796.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Biocytogen Pharmaceuticals (Beijing) is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%0×50×100×6886906257IGILFSL3264001267KWS601965SYNGENENSP688596688796.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Biocytogen Pharmaceuticals (Beijing) is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%688690IGILFSLSAGILITYKWS601965SYNGENE002091NSP300140VVX002310688796.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Biocytogen Pharmaceuticals (Beijing) is the large dot.

Biocytogen Pharmaceuticals (Beijing) competitors and peer comparison

Head to head with its named competitors (688796.SS vs OABI vs CRL vs ABCL)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Biocytogen Pharmaceuticals (Beijing) 688796.SS$2.09B-33%+40%24%73.0×31.0%
OmniAb OABI$741M+97%+91%-116%n/a60.6%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
AbCellera Biologics ABCL$3.60B+141%+92%-298%n/an/a
Genscript Biotech 1548.HK$8.69B+133%+53%12%294.1×36.9%

How Biocytogen Pharmaceuticals (Beijing) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Biocytogen Pharmaceuticals (Beijing) against its 20 peers (data as of 18 Nov 2026)
Measure688796.SSPeer medianRank in peer set
1-month return-27.8%+2.9%3rd lowest of 21
6-month return-32.9%+1.6%2nd lowest of 21
Distance from 52-week high-58.3%-28.2%2nd lowest of 21
Revenue growth (TTM)+40.5%+15.8%2nd highest of 20
Operating margin23.6%12.4%7th highest of 21
Forward P/E73.0×17.0×3rd most expensive of 18
Growth the price implies (Req g, 7 yrs)31.0%13.7%5th most demanding of 15
Growth delivered (Del g)+41.1%+11.4%highest of 14
Hurdle (Req g minus delivered)-10.1 pp-10.4 pp7th most demanding of 14
ROIC minus cost of capital+1.8 pp+0.5 pp9th highest of 20
EV / EBITDA25.3×10.8×most expensive of 12
Net debt / EBITDA-0.3×0.9×3rd least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Biocytogen Pharmaceuticals (Beijing) 688796.SSChina$2.09B-33%+40%24%73.0×31.0%+41.1%
Suzhou Nanomicro Technology 688690.SSChina$2.08B-1%+26%25%51.5×33.2%+35.2%
Sigurd Microelectronics 6257.TWTaiwan$2.10B-28%+18%24%11.3×n/an/a
International Gemological Institute IGIL.NSIndia$2.05B+33%+21%58%26.0×16.3%+37.6%
Firstsource Solutions FSL.NSIndia$2.04B+13%+20%12%20.4×19.2%+13.5%
TIC Solutions TICUnited States$2.15B+14%+39%-1%n/a32.6%n/a
Heron Neutron Medical 7799.TWTaiwan$2.15B+56%n/a-5,319%355.2×n/an/a
Ardentec 3264.TWOTaiwan$2.17B-26%+32%30%11.3×n/an/a
Sagility SAGILITY.NSIndia$2.26B+7%+28%18%17.0×11.2%+19.5%
Hui Lyu Ecological Technology Groups 001267.SZChina$2.28B-68%+90%10%133.5×n/an/a
KWS SAAT SE & Co KGaA KWS.DEGermany$2.30B-11%-1%13%12.7×-6.0%+4.4%
China Automotive Engineering Research Institute 601965.SSChina$2.31B-11%+12%24%13.8×-4.7%+7.9%
Syngene International SYNGENE.NSIndia$1.88B-8%-6%13%70.7×36.4%+11.4%
Jiangsu Guotai International 002091.SZChina$1.87B-15%+7%6%9.7×-21.2%+5.5%
Insperity NSPUnited States$1.86B+55%+2%0%19.6×19.4%+9.7%
CECEP Environmental Protection 300140.SZChina$2.37B-23%-2%23%n/a-1.9%+26.0%
Shanghai GenTech 688596.SSChina$2.37B+4%+4%2%68.2×n/an/a
Prosegur Compania de Seguridad PSG.MCSpain$1.82B+10%+4%6%12.2×-3.7%+6.7%
V2X VVXUnited States$2.45B+9%+13%4%11.7×-0.5%+26.3%
Beijing Orient EcoEnergy 002310.SZChina$1.75B-25%+35%12%n/a36.0%-47.6%
Hoist Finance HOFI.STSweden$1.75B+20%+16%30%12.2×n/an/a

Questions

Who are Biocytogen Pharmaceuticals (Beijing)'s main competitors?
Named competitors: Harbour BioMed (private or unlisted), OmniAb (OABI), Charles River Laboratories (CRL), AbCellera (ABCL), GenScript Biotech (1548.HK). The cockpit's measured peer set (industry) also includes Suzhou Nanomicro Technology (688690.SS), Sigurd Microelectronics (6257.TW), International Gemological Institute (IGIL.NS), Firstsource Solutions (FSL.NS), TIC Solutions (TIC), Heron Neutron Medical (7799.TW).
Is Biocytogen Pharmaceuticals (Beijing) expensive compared with its peers?
On forward p/e it trades at 73.0× against a peer median of 17.0×, 3rd most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 31% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Biocytogen Pharmaceuticals (Beijing) stock performed?
Over six months to 18 Nov 2026 the shares returned -32.9% against +1.6% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.